Amphastar Asks Jury To Nix $1B Momenta Infringement Case
By Brian Amaral · July 20, 2017, 9:30 PM EDT
Amphastar Pharmaceuticals on Thursday told a federal jury in Boston that generic competitor Momenta's "outrageous" dishonesty in developing standards for a lucrative blood thinner should end the company's patent infringement case....
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login